Catalyst Event

Merck and Co Inc (MRK) · Other

From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)

6/6/2026, 12:00:00 AM

OtherSentiment: Positive

The U.S. FDA granted orphan drug designation to Keytruda for the treatment of neuroendocrine prostate cancer; estimated 1% price impact due to niche market expansion, expected.

Korean Translation

미국 FDA는 신경내분비 전립선암 치료를 위해 키트루다를 희귀의약품으로 지정함. 시장 확장에 따른 약 1% 주가 영향 예상됨.

Related Recent Events

View Full Timeline
Merck and Co Inc (MRK) Other | A500PAM Catalyst Event | Indexed by Akros